Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Fiona M. Behan(Age UK), Mathew J. Garnett(Wellcome Sanger Institute), Julio Sáez-Rodríguez(European Bioinformatics Institute), Dieudonne van der Meer(Wellcome Sanger Institute), Piers Wilkinson(Wellcome Sanger Institute), Andrea Bertotti(University of Turin), Sarah Harper(Wellcome Sanger Institute), Gabriele Picco(Wellcome Sanger Institute), Giorgia Migliardi(University of Turin), Rizwan Ansari(Wellcome Sanger Institute), Livio Trusolino(University of Turin), Charlotte Beaver(Wellcome Sanger Institute), David A. Jackson(Wellcome Sanger Institute), Rita Santos(GlaxoSmithKline (United Kingdom)), Rachel Pooley(Wellcome Sanger Institute), Marika Pinnelli(Candiolo Cancer Institute), Carolyn Buser‐Doepner(GlaxoSmithKline (United States)), Francesco Sassi(Candiolo Cancer Institute), Emanuel Gonçalves(European Bioinformatics Institute), Euan A. Stronach(Age UK), Rebecca McRae(Wellcome Sanger Institute), Francesco Iorio(Human Technopole), Kosuke Yusa(Kyoto University), David J. Dow(GlaxoSmithKline (United Kingdom)), Yanhua Rao(GlaxoSmithKline (United States))
Cited by 1,417
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Drug repurposing: progress, challenges and recommendations
|Nature Reviews Drug Discovery|2018|4.6k
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k